quinidine sulfate
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 9
Of
9
Go to page
1
November 17, 2025
Whole blood cholinesterase activity in humans and ruminants: Comparison using a modified electrometric method.
(PubMed, Open Vet J)
- "Whole blood samples (8-10/species) were subjected to in vitro pseudo ChE inhibition using 50 µl of 1% quinidine sulfate with the objective of estimating the remaining true ChE in the blood...The results obtained demonstrate that human blood exhibits higher WBChE, pseudo ChE, and true ChE activities compared to those of ruminants. A comparative determination of WBChE activity using a simple modified electrometric method in humans and farm animals could serve as a valuable tool for collectively assessing cross-species exposure to pesticides."
Clinical • Journal
July 29, 2025
Gain-of-function mutations in Caenorhabditis elegans levamisole-sensitive nicotinic receptors evaluated at the single-channel level.
(PubMed, Biochem Biophys Res Commun)
- "The nematode Caenorhabditis elegans is a valuable model for studying both human neuromuscular disorders and parasitic nematodes. Quinidine sulfate, a therapeutic agent used to treat slow-channel CMS, reduced the abnormally prolonged channel openings of mutant L-AChRs. These findings demonstrate the evolutionary conservation of TM2 residues in nAChR activation, validate C. elegans as a model for human channelopathies, and support its use in exploring therapeutic interventions for nAChR-related disorders."
Journal • CNS Disorders
October 23, 2024
Rational quinidine dosage regimen for atrial fibrillation in Thoroughbred racehorses based on population pharmacokinetics.
(PubMed, Front Vet Sci)
- "Six healthy Thoroughbred horses were treated with 20 mg/kg quinidine sulfate dihydrate (16.58 mg/kg QND base) administered PO or 5 mg/kg quinidine hydrochloride monohydrate (4.28 mg/kg QND base) administered IV (single administration), and blood samples were taken regularly...Using simulations, different empirical dosing regimens were proposed to achieve plasma quinidine concentrations immediately or progressively, representing a tradeoff between optimizing therapeutic effects and minimizing adverse effects. A combination of these dosing regimens is recommended to gradually increase the therapeutic concentration levels of quinidine for safe and effective treatment of AF in racehorses."
Journal • PK/PD data • Atrial Fibrillation • Cardiovascular
May 21, 2023
Polymorphic Ventricular Tachycardia Storm After Coronary Artery Bypass Graft Surgery: A Form of 'Angry Purkinje Syndrome'.
(PubMed, Heart Lung Circ)
- "The Angry Purkinje Syndrome is a rare but important cause of ventricular tachycardia storm after CABG surgery and is mediated by short-coupled ventricular ectopy in the absence of acute myocardial ischaemia. This arrhythmia may be highly responsive to quinidine."
Journal • Surgery • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Heart Failure • Ventricular Tachycardia
October 04, 2022
Retrospective review of atrial fibrillation in Standardbred racehorses at a tertiary care facility in Atlantic Canada.
(PubMed, Can Vet J)
- "Key clinical message: To the authors' knowledge, this is the first published review to assess the athletic ability of Standardbred racehorses following cardioversion with enteral quinidine sulphate. Based on the current information, it does not appear that treatment of AF with quinidine sulphate affects future athletic performance in horses that achieved cardioversion."
Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular
January 28, 2022
QUINIDINE IS AN EFFECTIVE MEDICAL TREATMENT FOR MANAGEMENT OF IDIOPATHIC RECURRENT VENTRICULAR FIBRILLATION
(ACC 2022)
- "Trial of Sotalol did not reduce the episodes and amiodarone was not tolerated...Due to drug-refractory VF, we decided to proceed with trial of Quinidine sulfate at 200mg three times a day with anticipation to escalate... Quinidine was extensively used anti-arrhythmic drugs (AAD) before current day AADs were available. Increased recognition of the side effects of Quinidine and mortality risk led to reduced interest in its use. However, Quinidine has a niche role in selected disease states like idiopathic VF, Brugada syndrome and short QT syndrome."
Atrial Fibrillation • Cardiovascular • Cerebral Palsy • CNS Disorders • Genetic Disorders • Heart Failure
December 12, 2021
Successful Use of Quinidine to Treat Refractory Myoclonic and Astatic Seizures in a Patient with KCNT1 Variant
(AES 2021)
- "Funding: None.; Rationale: We present successful use of quinidine sulfate for treatment of myoclonic and astatic seizures refractory to a regimen of multiple anti-epileptic drugs in a 2-year-old female with a heterozygous KCNT1 mutation, c.2797C >T (p.Arg933Cys), a variant of unknown significance. Mutations in the KCNT1 gene have been identified as gain of function mutations associated with autosomal dominant nocturnal frontal lobe epilepsy, or early infantile epileptic encephalopathy, and malignant migrating focal seizures of infancy. To date, our patient has achieved seizure-free status after being started on quinidine and has been simultaneously weaned off levetiracetam and phenobarbital. Thus, quinidine may be a viable option for treatment of patients with KCNT1 mutations who have myoclonic and astatic seizures refractory to traditional antiseizure medications."
Clinical • CNS Disorders • Epilepsy • Infectious Disease • MRI
September 30, 2021
Efficacy and Tolerability of Quinidine as Salvage Therapy for Monomorphic Ventricular Tachycardia in patients with Structural Heart Disease.
(PubMed, J Cardiovasc Electrophysiol)
- "Quinidine therapy has limited tolerability and long-term efficacy when used in the management of amiodarone-refractory scar related MMVT."
Clinical • Journal • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Heart Failure • Hematological Disorders • Thrombocytopenia • Ventricular Tachycardia
August 16, 2021
Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects
(clinicaltrials.gov)
- P1; N=72; Completed; Sponsor: Enanta Pharmaceuticals; Recruiting ➔ Completed
Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation
1 to 9
Of
9
Go to page
1